As expected, last week the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit in US District Court for the District of Columbia to block a new federal rule that allows states to import less costly prescription drugs from Canada. Also last week, the Canadian Minister of Health issued an order prohibiting the bulk export […]
Author Archive for: jennifer-reck
About Jennifer Reck
Jennifer Reck is project director of NASHP’s Center for State Prescription Drug Pricing. The center works with states to develop model policies to address drug prices, tracks legislation and implementation, and provides technical assistance. Since joining NASHP in 2015, she has designed and implemented technical assistance for state learning collaboratives to advance evidence-based policymaking and alternative payment models. She has also directed evaluation teams analyzing delivery system and payment reforms, including State Innovation Models, and led efforts to disseminate findings from a federal initiative to advance evidence-based preventive care.
Prior to joining NASHP in 2015, Jennifer was Maine Medical Association’s (MMA) director of grants management, where she engaged physicians in payment reform as well as outreach and advocacy efforts to implement the Affordable Care Act. She also directed the MMA’s academic detailing program – the Maine Independent Clinical Information Service – an educational outreach program to promote evidence-based primary care. She has also worked as a policy analyst at Prescription Policy Choices, providing states with policy models and technical assistance to address clinical and cost concerns related to prescription drugs, and as a publishing editor at Elsevier Science, managing its portfolio of health policy journals.
She received her master’s degree from Cornell University in Science and Technology Studies and her bachelor’s degree in the history and philosophy of science from Bard College.
Entries by Jennifer Reck
Low-income individuals and communities of color, already besieged by poor access to health care, limited insurance coverage, and other health inequities exposed by COVID-19, also suffer another health disparity – they are among the hardest hit by continually rising prescription drug prices. Since 2017, states across the nation have taken action to lower rising drug […]
Earlier this month, the Health and Human Services (HHS) Secretary published the final rule for state importation of prescription drugs from Canada. To receive federal approval for their Section 804 importation programs (SIPs), the six states with laws enabling importation (VT, FL, ME, CO, NM, and NH) must meet the rule’s safety and cost-savings requirements […]
Today, the US Supreme Court is scheduled to hear oral arguments in a legal challenge of an Arkansas law that regulates the reimbursement rates that pharmacy benefit managers (PBMs) pay to pharmacies.
Six states with laws enabling the importation of prescription drugs from Canada – Vermont, Florida, Maine, Colorado, New Mexico, and New Hampshire – are awaiting publication of federal rules currently under review by the Office of Management and Budget. They are eager to see if the final rules address key concerns submitted by the National […]
Unpredictable and unrelenting drug price increases drive up health insurance premiums and challenge states’ public purchasers as they weigh escalating costs against balanced budget requirements. The National Academy for State Health Policy’s (NASHP) newest model law, an Act to Protect Consumers from Unsupported Price Increases on Prescription Drugs, levies hefty fines on manufacturers that impose […]
Getting a grip on pharmaceutical manufacturers’ pricing strategies is a 2020 priority for the National Academy for State Health Policy (NASHP), but how drugs are marketed also significantly impacts spending on drugs. In 2016, pharmaceutical companies spent $6 billion on direct-to-consumer advertising, but a whopping $20.3 billion to market their brand name drugs to health […]
As the nation grapples with the pandemic, new research has identified dexamethasone, a low-cost generic drug, as a promising treatment for certain COVID-19 patients. But consumers worry – will its cost remain low? Will new treatments be affordable?
The Centers for Medicare & Medicaid Services (CMS) has proposed a new rule with provisions designed to advance value-based purchasing (VBP) arrangements with drug manufacturers. Comments about the proposal are due July 20, 2020.
Removing wasteful drugs from formularies and replacing them with drugs that offer the same benefits at a lower cost, helps state employee health plans and other public purchasers reduce spending without sacrificing value – a critical strategy for savings as states face tremendous budget pressures.